Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Stereotaxis, Inc.

Get SEC filing alerts via email and in your feed for Stereotaxis, Inc.

STXS

Stereotaxis, Inc.

About Stereotaxis, Inc.

Stereotaxis designs and markets robotic systems for minimally invasive interventional procedures, primarily in electrophysiology and cardiology. Its core products include magnetic navigation systems, integrated information solutions, and compatible disposable devices. The company enhances procedural precision, safety, and efficiency, enabling complex treatments with broader physician access. Operating globally, it leverages strategic partnerships, regulatory expertise, and innovative R&D to advance robotic medical technology.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Stereotaxis, Inc.

1
1
Stereotaxis, Inc. Stereotaxis Reports 16% Revenue Decline in Q1 2026, Plans Acquisition of Robocath

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Stereotaxis, Inc. Stereotaxis Reports 20% Revenue Increase to $32.4 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Stereotaxis, Inc. Stereotaxis Reports 19% Revenue Decline and $6.5 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Stereotaxis, Inc. Stereotaxis Reports 95% Revenue Growth to $8.8 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Stereotaxis, Inc. Stereotaxis Reports 9% Revenue Increase to $7.5 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Stereotaxis, Inc. Stereotaxis Reports Slight Revenue Increase and Acquisition of Access Point Technologies

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Stereotaxis, Inc. Stereotaxis Reports 7% Decline in Revenue for Nine Months Ended September 30, 2024, Despite 18% Q3 Growth

Via official filing (AI summary) | over 1 year ago | 0 comments